Novo Nordisk reports strong sales of Wegovy, propelling shares up 9%. Despite supply constraints, volumes are expected to ...

Doctors and specialists use Wegovy to support patients in reducing their body mass index and mitigating cardiovascular risks.

Novo Nordisk (CSE: NOVOb) has been placed on JPMorgan’s Catalyst Watch list, signaling heightened anticipation as the company approaches a pivotal moment in its ...

Wegovy and Ozempic drove Novo Nordisk to record bumper sales since the launch. In fact, the success story has turned the ...

Novo's drugs Ozempic and Wegovy have slimmed down Hollywood stars ... And today, Novo Nordisk's success and the spike in demand for Ozempic is fattening the country's economy—creating thousands ...

Popular weight-loss drugs are helping some runners lose weight and crush PRs. Experts have some real concerns.

Novo Nordisk's third-quarter sales for Wegovy exceeded expectations, relieving investors concerned about demand slowdown.

With ocedurenone gone, the only CKD program still listed in Novo’s pipeline is semaglutide—the main ingredient behind ...

‘I'm A Dietitian Who Lost 50 Pounds On Mounjaro’ Zepbound May Now Be Easier to Get—And Cheaper Can Ozempic, Wegovy And More ...

BEN Shephard awkwardly stepped in on today’s This Morning when former politician Nadine Dorries repeatedly plugged a ...

Novo Nordisk (NYSE:NVO) (CSE:NOVOb) reported strong growth for the first nine months of 2024, with sales jumping by 23% in Danish kroner and 24% at constant exchange rates, reaching DKK 204.7 billion.